2.639
0.009 (0.34%)
0.009 (0.34%)
Upgrade to Real-Time
Regular Market
Volume | 1,849,156 |
|
|||||
News | - | ||||||
Day High | 2.70 | Low High |
|||||
Day Low | 2.60 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Inovio Pharmaceuticals Inc New | INO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.61 | 2.60 | 2.70 | 2.63 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,844 | 1,849,156 | $ 2.66 | $ 4,923,700 | - | 1.38 - 9.59 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:24:05 | 2,000 | $ 2.639 | USD |
Inovio Pharmaceuticals Inc New Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 658.17M | 249.40M | 245.62M | $ 1.77M | $ - | -1.45 | -1.60 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 1.09M | 2.70% |
Inovio Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.41 | 2.70 | 2.02 | 2.46 | 7,983,890 | 0.229 | 9.5% |
1 Month | 1.99 | 2.70 | 1.815 | 2.21 | 6,526,979 | 0.649 | 32.61% |
3 Months | 2.16 | 2.70 | 1.38 | 1.95 | 6,581,121 | 0.479 | 22.18% |
6 Months | 3.35 | 4.00 | 1.38 | 2.43 | 5,953,749 | -0.711 | -21.22% |
1 Year | 9.1765 | 9.59 | 1.38 | 4.09 | 5,090,661 | -6.54 | -71.24% |
3 Years | 2.28 | 35.50 | 1.38 | 12.17 | 12,341,565 | 0.359 | 15.75% |
5 Years | 5.64 | 35.50 | 1.38 | 11.76 | 7,890,147 | -3.00 | -53.21% |
Inovio Pharmaceuticals Description
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. |